Dr. Thomas Michael Reilly, MD

Dr. Reilly practices at Adventist Health Bakersfield in Bakersfield, California, part of Adventist Health.

Dr. Reilly's NPI, 1265475115, was assigned on June 14, 2006. Dr. Reilly graduated from St. George's University School of Medicine in 1988. Dr. Reilly holds California license A48776.

Dr. Reilly's primary practice is Adventist Health Bakersfield, at 2615 Chester Avenue, Bakersfield, CA 93301 in Kern County. The practice phone is (661) 395-3000.

Dr. Reilly's primary practice is Adventist Health Bakersfield in Bakersfield, California, part of Adventist Health. Dr. Reilly is also affiliated with Sherman Oaks Hospital. The medical group on file is Vituity. Dmand AI also links Dr. Reilly to 1 more hospital and 8 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Reilly practices, 3 sites in all. Vendor and product names are available with a free account.

Emergency medicine is Dr. Reilly's primary specialty in the NPI Registry, under taxonomy code 207P00000X. Dr. Reilly is board certified in emergency medicine by the American Board of Emergency Medicine. Dr. Reilly is licensed in California.

CMS data shows 847 Medicare services from Dr. Reilly across 4 procedure codes in 2024, for 496 Medicare patients. Medicare paid $71,045 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 496 Medicare patients who saw Dr. Reilly in 2024. The largest group is 65 to 74, with 195 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 69% are also on Medicaid. Their average risk score is 2.85, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Reilly's median patient age at 47, with 58% women.

In 2024, Dr. Reilly wrote 409 Medicare Part D claims for 281 patients. 95% of them were for generic drugs. CMS names the drug for 300 of them, across 11 drugs with 11 or more claims each, at $2,196 in total drug cost. In 2023, CMS named 250 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Dr. Reilly for performance year 2024, reported as part of a group. Dr. Reilly accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links Dr. Reilly to 2 clinical trials. Conditions studied include Alzheimer Disease and Tauopathies. AstraZeneca sponsors the most, 2. Open Payments lists research payments to Dr. Reilly that name 2 trials.

CMS Open Payments shows 1 general payment to Dr. Reilly from 1 drug or device company in 2021. Food and beverage make up the largest share, 100% of the total. DePuy Synthes Sales Inc. paid the most, $35. It also lists 10 research payments totaling $28,243 from 2016 to 2018, naming 2 clinical trials.

Dr. Reilly graduated from St. George's University School of Medicine in 1988.

Dr. Reilly is in network with 4 carriers, including Blue Cross Blue Shield of Massachusetts, HCSC and CMS Medicare. Medicare plans come from the most carriers, 4. Check the plan with the practice before a visit.